Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 5 glepaglutide trial in short bowel syndrome with intestinal failure
NL-OMON59103Phase 3Recruiting
- Sponsor
- Zealand Pharma
- Start
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Change in weekly parenteral support volume from baseline to Week 24. Started Feb 2026; status: recruiting.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON59103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59103.